 Carolyn Welsh
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiolitis Obliterans | 2 | 2015 | 68 | 0.870 |
Why?
| | Societies, Medical | 2 | 2015 | 764 | 0.590 |
Why?
| | Lung Transplantation | 1 | 2015 | 311 | 0.470 |
Why?
| | Lung Diseases | 4 | 2004 | 725 | 0.370 |
Why?
| | Pulmonary Medicine | 2 | 2014 | 84 | 0.350 |
Why?
| | Hypercapnia | 1 | 2007 | 37 | 0.340 |
Why?
| | Venous Thrombosis | 2 | 2007 | 133 | 0.340 |
Why?
| | Systems Biology | 1 | 2007 | 53 | 0.320 |
Why?
| | Deoxycytidine | 1 | 2007 | 141 | 0.310 |
Why?
| | Syphilis, Cutaneous | 1 | 2004 | 2 | 0.280 |
Why?
| | Treponema pallidum | 1 | 2004 | 14 | 0.270 |
Why?
| | Endotoxins | 4 | 1993 | 265 | 0.270 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2007 | 222 | 0.270 |
Why?
| | Pneumonia | 2 | 2007 | 559 | 0.260 |
Why?
| | Physician's Role | 1 | 2003 | 217 | 0.210 |
Why?
| | Pentoxifylline | 2 | 1991 | 21 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1390 | 0.180 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1209 | 0.150 |
Why?
| | Prazosin | 1 | 2015 | 39 | 0.140 |
Why?
| | Dreams | 1 | 2015 | 14 | 0.140 |
Why?
| | Pneumonia, Mycoplasma | 1 | 1995 | 41 | 0.140 |
Why?
| | Capillary Permeability | 4 | 1993 | 162 | 0.140 |
Why?
| | Neutrophils | 4 | 1991 | 1340 | 0.140 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 390 | 0.140 |
Why?
| | Syndrome | 1 | 2015 | 342 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1159 | 0.130 |
Why?
| | Palliative Care | 1 | 2019 | 608 | 0.120 |
Why?
| | Pulmonary Ventilation | 1 | 1993 | 82 | 0.120 |
Why?
| | Pulmonary Embolism | 3 | 1999 | 176 | 0.120 |
Why?
| | Salmonella enteritidis | 2 | 1989 | 16 | 0.120 |
Why?
| | Acclimatization | 1 | 1993 | 127 | 0.120 |
Why?
| | Respiratory Insufficiency | 1 | 1995 | 285 | 0.110 |
Why?
| | Antibiotics, Antitubercular | 1 | 1991 | 37 | 0.110 |
Why?
| | Pulmonary Circulation | 2 | 1993 | 467 | 0.100 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 308 | 0.100 |
Why?
| | Gastrectomy | 1 | 1991 | 81 | 0.100 |
Why?
| | Tuberculosis, Pulmonary | 1 | 1991 | 127 | 0.100 |
Why?
| | Altitude | 1 | 1993 | 399 | 0.090 |
Why?
| | Theobromine | 1 | 1988 | 2 | 0.090 |
Why?
| | Humans | 19 | 2019 | 114578 | 0.090 |
Why?
| | Lung | 6 | 1999 | 3558 | 0.090 |
Why?
| | Pulmonary Artery | 2 | 1993 | 1081 | 0.090 |
Why?
| | Quality of Life | 1 | 2019 | 2230 | 0.090 |
Why?
| | Aging | 1 | 1998 | 1708 | 0.090 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2015 | 616 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 1991 | 281 | 0.090 |
Why?
| | Diagnosis | 1 | 2007 | 13 | 0.080 |
Why?
| | Blood Proteins | 2 | 1993 | 258 | 0.080 |
Why?
| | Carboplatin | 1 | 2007 | 140 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2004 | 2379 | 0.080 |
Why?
| | Heart Failure | 1 | 2019 | 1944 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1541 | 0.080 |
Why?
| | Dyspnea | 1 | 2007 | 187 | 0.070 |
Why?
| | Asthma | 2 | 2014 | 2039 | 0.070 |
Why?
| | Pulmonary Edema | 3 | 1993 | 159 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2007 | 191 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 1991 | 962 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2004 | 194 | 0.060 |
Why?
| | Risk | 1 | 2007 | 943 | 0.060 |
Why?
| | Male | 12 | 2015 | 60818 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2015 | 2181 | 0.060 |
Why?
| | Activated Protein C Resistance | 1 | 2003 | 1 | 0.060 |
Why?
| | Medical Laboratory Science | 1 | 2003 | 8 | 0.060 |
Why?
| | Factor V | 1 | 2003 | 16 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2004 | 179 | 0.060 |
Why?
| | Information Systems | 1 | 2003 | 70 | 0.060 |
Why?
| | Ossification, Heterotopic | 1 | 2002 | 19 | 0.060 |
Why?
| | Obesity | 2 | 2007 | 2643 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2847 | 0.060 |
Why?
| | Workload | 1 | 2003 | 137 | 0.060 |
Why?
| | Certification | 1 | 2003 | 112 | 0.060 |
Why?
| | Canada | 1 | 2003 | 325 | 0.060 |
Why?
| | Age Distribution | 1 | 2003 | 396 | 0.060 |
Why?
| | Sex Distribution | 1 | 2003 | 390 | 0.060 |
Why?
| | Patient Readmission | 1 | 2007 | 664 | 0.050 |
Why?
| | Employment | 1 | 2003 | 164 | 0.050 |
Why?
| | Aged | 6 | 2007 | 20219 | 0.050 |
Why?
| | Hypoxia | 1 | 2007 | 924 | 0.050 |
Why?
| | Needs Assessment | 1 | 2003 | 343 | 0.050 |
Why?
| | Middle Aged | 7 | 2004 | 28854 | 0.050 |
Why?
| | Dogs | 3 | 1993 | 430 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2004 | 555 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1783 | 0.050 |
Why?
| | Calcinosis | 1 | 2002 | 292 | 0.050 |
Why?
| | Snoring | 1 | 1998 | 14 | 0.050 |
Why?
| | Respiratory Muscles | 1 | 1998 | 29 | 0.050 |
Why?
| | Lung Diseases, Obstructive | 1 | 1998 | 53 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2004 | 4950 | 0.050 |
Why?
| | Pulmonary Gas Exchange | 1 | 1998 | 132 | 0.050 |
Why?
| | Respiratory Mechanics | 1 | 1998 | 82 | 0.040 |
Why?
| | Carcinoma, Small Cell | 1 | 1998 | 169 | 0.040 |
Why?
| | Ventilation-Perfusion Ratio | 2 | 1998 | 14 | 0.040 |
Why?
| | Sleep Apnea Syndromes | 1 | 1998 | 95 | 0.040 |
Why?
| | Advance Care Planning | 1 | 2019 | 178 | 0.040 |
Why?
| | Chronic Disease | 2 | 2019 | 1649 | 0.040 |
Why?
| | Tuberculosis | 1 | 1998 | 246 | 0.040 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 25 | 0.040 |
Why?
| | Physicians | 1 | 2003 | 727 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 1029 | 0.040 |
Why?
| | Patient Care Team | 1 | 2019 | 531 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2003 | 2187 | 0.030 |
Why?
| | Adult | 5 | 2003 | 32077 | 0.030 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 1993 | 3 | 0.030 |
Why?
| | Vital Capacity | 1 | 1993 | 249 | 0.030 |
Why?
| | Spirometry | 1 | 1993 | 288 | 0.030 |
Why?
| | Female | 7 | 2015 | 63070 | 0.030 |
Why?
| | Sleep | 1 | 1998 | 731 | 0.030 |
Why?
| | Proteins | 2 | 1989 | 952 | 0.030 |
Why?
| | Chromium Radioisotopes | 1 | 1991 | 3 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 1993 | 550 | 0.030 |
Why?
| | Coronary Vessels | 1 | 1993 | 271 | 0.030 |
Why?
| | Time Factors | 2 | 2015 | 7029 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1991 | 63 | 0.030 |
Why?
| | Albumins | 1 | 1991 | 98 | 0.030 |
Why?
| | Permeability | 1 | 1991 | 160 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4741 | 0.030 |
Why?
| | Vascular Surgical Procedures | 1 | 1993 | 251 | 0.030 |
Why?
| | Intestinal Absorption | 1 | 1991 | 112 | 0.030 |
Why?
| | Radiography | 1 | 1993 | 850 | 0.030 |
Why?
| | Prognosis | 1 | 1998 | 3546 | 0.030 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1998 | 986 | 0.020 |
Why?
| | Cyclic AMP | 1 | 1991 | 285 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 1991 | 165 | 0.020 |
Why?
| | Complement C5 | 1 | 1989 | 83 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2015 | 9190 | 0.020 |
Why?
| | Radionuclide Imaging | 2 | 1999 | 155 | 0.020 |
Why?
| | Neutropenia | 1 | 1988 | 130 | 0.020 |
Why?
| | Cattle | 1 | 1991 | 964 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 1994 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1993 | 1242 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 1991 | 1004 | 0.020 |
Why?
| | Exercise | 1 | 1998 | 1755 | 0.020 |
Why?
| | Anti-Arrhythmia Agents | 1 | 1987 | 148 | 0.020 |
Why?
| | Hemodynamics | 2 | 1988 | 1103 | 0.020 |
Why?
| | United States | 1 | 2003 | 12551 | 0.020 |
Why?
| | Blood Pressure | 1 | 1993 | 1726 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 1998 | 2191 | 0.020 |
Why?
| | Animals | 5 | 1993 | 34690 | 0.020 |
Why?
| | Tidal Volume | 1 | 2004 | 77 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1188 | 0.020 |
Why?
| | Survival Analysis | 1 | 2007 | 1410 | 0.020 |
Why?
| | Factor VIII | 1 | 2003 | 48 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2003 | 56 | 0.020 |
Why?
| | Myocardium | 1 | 1988 | 1093 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1991 | 4281 | 0.010 |
Why?
| | Comorbidity | 1 | 2007 | 1645 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2003 | 290 | 0.010 |
Why?
| | Review Literature as Topic | 1 | 2002 | 82 | 0.010 |
Why?
| | Kidney | 1 | 1988 | 1197 | 0.010 |
Why?
| | Risk Factors | 2 | 2007 | 9078 | 0.010 |
Why?
| | Sex Factors | 1 | 2007 | 1971 | 0.010 |
Why?
| | Haplotypes | 1 | 2003 | 418 | 0.010 |
Why?
| | Genome, Human | 1 | 2003 | 300 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 1109 | 0.010 |
Why?
| | Child, Preschool | 1 | 1995 | 9651 | 0.010 |
Why?
| | False Negative Reactions | 1 | 1999 | 67 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3280 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2003 | 661 | 0.010 |
Why?
| | Iothalamate Meglumine | 1 | 1998 | 5 | 0.010 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 1998 | 7 | 0.010 |
Why?
| | Critical Illness | 1 | 2004 | 583 | 0.010 |
Why?
| | Iohexol | 1 | 1998 | 18 | 0.010 |
Why?
| | Angiography, Digital Subtraction | 1 | 1998 | 24 | 0.010 |
Why?
| | Veterans | 1 | 2007 | 951 | 0.010 |
Why?
| | Reference Standards | 1 | 1998 | 192 | 0.010 |
Why?
| | Angiography | 1 | 1998 | 162 | 0.010 |
Why?
| | Probability | 1 | 1998 | 335 | 0.010 |
Why?
| | Prospective Studies | 2 | 1999 | 6288 | 0.010 |
Why?
| | Colorado | 1 | 2007 | 4488 | 0.010 |
Why?
| | Radiopharmaceuticals | 1 | 1998 | 197 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1999 | 6819 | 0.010 |
Why?
| | Adolescent | 1 | 1995 | 18658 | 0.010 |
Why?
| | Child | 1 | 1995 | 17860 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2052 | 0.010 |
Why?
| | DNA | 1 | 2003 | 1352 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 993 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2003 | 3249 | 0.010 |
Why?
| | Contrast Media | 1 | 1998 | 421 | 0.010 |
Why?
| | Anticoagulants | 1 | 1999 | 538 | 0.010 |
Why?
| | Ultrasonography | 1 | 1999 | 783 | 0.010 |
Why?
| | Oxygenators | 1 | 1993 | 5 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 743 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1920 | 0.010 |
Why?
| | Blood Vessels | 1 | 1993 | 191 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 1999 | 2926 | 0.010 |
Why?
| | Complement System Proteins | 1 | 1993 | 265 | 0.010 |
Why?
| | Procainamide | 1 | 1987 | 5 | 0.010 |
Why?
| | Quinidine | 1 | 1987 | 7 | 0.010 |
Why?
| | Thiourea | 1 | 1987 | 39 | 0.010 |
Why?
| | Lidocaine | 1 | 1987 | 42 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1987 | 491 | 0.010 |
Why?
| | Organ Size | 1 | 1987 | 503 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 304 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1987 | 1229 | 0.000 |
Why?
| | Retrospective Studies | 1 | 1999 | 11642 | 0.000 |
Why?
| | Rats | 1 | 1987 | 6201 | 0.000 |
Why?
|
|
Welsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|